The compound, 5-nitro-1,2,4-triazol-3-one, (NTO) is an explosive that performs similar to RDX but has reduced sensitivity compared to RDX. Routine safety assessments including toxicity testing have been performed with NTO. NTO has been demonstrated to affect testes weights in orally dosed rats. One possible mode of action for adverse testicular effects is hormonal (endocrine) disregulation. A series of in vitro bioassays were performed to assess if NTO disrupts the endocrine system. The assays performed were estrogen receptor binding, androgen receptor binding, estrogen transactivation, aromatase, and steroidogenesis. The endpoints of these assays contribute to a weight of evidence (WoE) strategy for determining NTO endocrine disruption. No NTO effects on the tested in vitro endpoints were observed and using a WoE approach, NTO does not appear to directly affect testosterone or estrogen mediated endocrine regulation. 
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Overview
The compound, 5-nitro-1,2,4-triazol-3-one, (NTO) has been demonstrated to affect testes weight in rat oral administration 14-day and 90-day studies. Additionally, testicular atrophy and hypospermia were observed in the 90-day study. The following studies were conducted to test the possibility that NTO is an endocrine disrupting compound (EDC). A weight of evidence (WoE) approach described by the USEPA was used as a guideline for evaluating NTO. A WoE strategy improves the sensitivity of and reliability for determining the potential EDC impact on hormonal pathways.
Purpose
As the next step for assessing NTO testicular toxicity, a series of bioassays that measure endocrine mediated endpoints were performed. Determining if NTO acts as an endocrine disruptor is important because environmentally persistent chemicals that impact reproduction can be highly regulated and receive a great deal of scrutiny from the EPA, which can result in restrictions on the use of these compounds by the U.S. Army.
Conclusions
NTO was tested in nine endocrine disruptor bioassays. Five of these assays were in vitro: estrogen receptor binding, androgen receptor binding, estrogen transactivation, aromatase, and steroidogenesis. No NTO effects on these endpoints were observed. Using a WoE approach, NTO does not appear to directly affect testosterone-or estrogen-mediated regulation.
Recommendation
The testicular toxicity of NTO in rats is well documented by USAPHC. The results from the Tier 1 in vitro screen do not support that NTO disrupts estrogen or androgen (as testosterone) endpoints. Metabolites are not directly tested with these methodologies and, if known, should be included in future EDC Tier 1 assessments. The mode of action for NTO testicular effects should be assessed with timed exposures so that the sequence of toxicity events can be observed using histopathological endpoints.
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Background
The endocrine system produces hormones that control the growth, development, reproduction, and metabolism of the body (Hiller-Sturmhofel and Bartke, 1998) . The endocrine glands include the hypothalamus, pituitary, adrenal, ovaries, testes, thyroid, parathyroid, and pancreas. In response to a specific stimulus, hormones are released from these glands and trigger a cascade of reactions that will modify the target cells' function or activity. Hormone production and secretion is tightly controlled by feedback responses so that homeostasis is maintained. Additionally, this highly regulated system allows for proper developmental staging. One example of this type of regulation is sexual maturation. Chemicals that disrupt these processes are called endocrine disrupting chemicals/compounds or EDCs. Chemicals that act as EDCs and specifically target reproductive hormones are of great interest as there is the potential for a negative impact on ecological species at the population level and on human health.
The USEPA was authorized in 1996 to regulate substances that may act like estrogen [21 U.S.C. 346a(p)]. Subsequently, the USEPA adopted a two-tiered screening and testing strategy--endocrine disruption screening program (EDSP)--and expanded the program to include androgen and thyroid hormonal pathways and ecological effects [Dec. 28, 1998 (63 FR 71542) ]. A testing battery was developed by the USEPA and peer-reviewed; see Table 1 .
Statement of the Problem
NTO is a testicular toxicant. One possible mode of action for this type of effect is inhibition or disruption of reproductive hormone function. A series of bioassays suitable for screening estrogen, androgen, and thyroid endpoints has been identified by the USEPA. The USAPHC Toxicology Portfolio has used this test battery as a reference for identifying a series of in vitro tests to screen NTO for endocrine effects. The in vitro approaches are of relative low cost and provide key information regarding the potential mode of action for NTO toxicity.
Methods
General Approach
The methods that were used for the series of tests reported here are based on the Test Guidelines in Table 1 . Modifications or substitutions to these methods were made to accommodate recent scientific data the support the use of alternative approaches. The details for each assay and any substitutions that were made are described below.
Estrogen and Androgen Receptor Binding
The estrogen and androgen receptor binding assays were performed by Ricerca Biosciences, LLC. Taiwan, R.O.C. The USEPA test guideline uses a radiolabeled endpoint for these assays and it was deemed cost and time efficient to use Ricerca as they are equipped and approved for using radiolabeled reagents.
The Ricerca Biosciences screen uses recombinant receptors for the assays. The androgen receptor is of rat origin expressed in bacteria and the estrogen alpha and beta receptors are of human origin expressed in Sf9 cells (Traish et al., 1986; Chang and Liao, 1987; Obourn et al., 1993 ). The concentration range tested was 3 nM to 30 µM NTO. The experimental conditions for the ER and AR binding assays are provided in the Ricerca report; Appendix B.
Aromatase Assay
The CYP19/Methoxy-4-trifluoromethyl-coumarin (MFC) High throughput Inhibition Screening Kit (Cat# 459520; Lot # 2177659) was used to screen NTO for potential inhibition of CYP19 catalytic activity (GenTest, BDBiosciences, Woburn MA). The storage conditions and protocol provided with the kit were followed; see Appendix C. The kit included the following reagents: 7-methoxy-4-trifluormethyl coumarin (fluorescent substrate), glucose 6-phosphate dehydrogenase, cofactors, CYP19 enzyme, phosphate buffer-pH 7.4, positive control inhibitor (ketoconazole), and metabolite standard (7-hydroxy-4-trifluormethyl coumarin). Briefly, on the day of the assay, reagents were removed from storage (-80 O C) and thawed on ice. Twenty-five mLs of molecular grade H 2 0 (Cat# SH 30538LS; Hyclone/ThermoFisher, US) and 2 mLs phosphate buffer were warmed to 37 O C. The ketoconazole stock was reconstituted in 36 µL acetonitrile (Sigma-Aldrich, US). NADPH-Cofactor mix was prepared per the protocol and 144 µL per well (96-well plate; Costar-black wall) was dispensed. Test compound was added to primary test wells and serially diluted (1:3) across the 96-well plate. The process was repeated for the ketoconazole wells. The plate was then incubated for 10 min at 37 O C. During the incubation, the enzyme-substrate mix was prepared and added to the appropriate wells after the 10 minute incubation. The plate was returned to 37 O C for an additional 30 minute incubation. At the conclusion of the 30 minute incubation, stop solution (stop reagent plus 
Estrogen Receptor Transactivation Assay
The BG1Luc4E2 cell line was used for this assay (Rogers and Denison, 2000) . The BG1Luc4E2 cell line is of human ovarian cancer origin and is stably transfected with a plasmid containing an estrogen response element pGudLuc7.0. The BG1Luc4E2 assay has been validated by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM). The cell line can be used to evaluate both the ER alpha and ER beta ligand mediated responses The NICEATM protocol was used as a guideline for the BG1Luc4E2 assay. Cells were cultured and maintained using standard tissue culture aseptic practices. Cells were maintained in complete medium (RPMI 1640 (-phenol red) Lot # 17105058, ThermoFisher, US; 0.9 percent Penicillinstreptomycin Cat# SV30010, ThermoFisher, US, 8 percent fetal bovine serum (FBS-Lot # ASA28574; Hyclone, Logan UT); 2 mM L-glutamine (Life Technologies, Carlsbad CA); 37 O C +/-1 O C, 90 percent +/-5 percent humidity, and 5 percent +/-1 percent CO 2 /air.). Cells were subcultured when at ~80 percent confluence by decanting the medium, rinsing the adherent cells with 10 mLs of phosphate buffered saline (PBS) without Ca +2 or Mg +2 (Cat# SH30028LS, Hyclone/ThermoFisher, US), dissociating the cells from the flasks (T-25, T-75, and T-150 plug cap flasks, as appropriate; Corning, ThermoFisher US) with trypsin/EDTA (Cat # 154000-54; Life Technologies, Carlsbad CA) for 3-5 minutes, neutralizing the trypsin with fresh media, and dispensing the cells at a 1:4 ratio into new flasks. Cells were reselected on G418 (Cat# MT30234CR ThermoFisher, US) after receipt from UC Davis and after 5 subcultures. Prior to experimental treatment, the cells were conditioned into estrogen free media (EFM) by replacing the maintenance medium with EFM (Dulbecco's Modification of Eagle's Medium (DMEM) Cat# D1145, Sigma-Aldrich, US; 4.5 percent charcoal/dextran-treated FBS, Cat# SH30068.03, HyClone, Logan UT; 2mM L-Glutamine and 0.9 percent penicillinstreptomycin, Cat# SV30010, ThermoFisher, US) for 48 hrs prior to initiating the experiment.
For the transactivation experiments, BG1Luc4E2 cells were plated at a density of 2x10 4 cells/well (volume 100 µL; EFM medium) in 96 well plates (Costar-white sided, ThermoFisher, US) and incubated overnight using the standard conditions described above. Dilution series of the positive controls estradiol (E2), 17-alpha estradiol (17-EE), diethylstilbestrol (DES), methoxyclor, and ethylparaben were prepared in dimethyl sulfoxide (DMSO) all from Sigma-Aldrich, US; NTO dilutions were prepared in DMSO; see Table 2 for concentrations. The negative control was vehicle only (0.05 percent DMSO final concentration). Test and control chemicals were added to duplicate wells in a volume of 100 µL per well so that the final volume per well was 200 µL. The test plates were returned to the incubator for 24 hours. Before measuring the luminescence, cells were observed microscopically for signs of cytotoxicity. The Steady Glo ® assay system (Cat# E2510, Promega, Madison WI) was used to develop the luminescence signal. To measure the luminescence, the media was aspirated from the wells and 100 µL RPMI-1640 was added to all test wells on the plate followed by 100 µL of reconstituted Steady-Glo reagent. Cells were incubated for 15 minutes in the dark and then luminescence was detected using plate reader (Synergy HT, Biotek, Winooski VT). Data were analyzed by subtracting the background signal (DMSO control) from the test signal and plotting the results graphically. Two criteria were used to determine a positive signal. First, the standard deviation of the DMSO control x 3 added to the DMSO signal was used as the minimum value for a positive signal. A dose-dependent response where at least two concentrations were above the minimal positive signal was used as the second criteria.
Steroidogenesis Assay H295R cell line
The H295R cell line (Cat# CRL-2128) was purchased from the American Type Culture Collection (ATCC) Manassas, VA. Cells were cultured according to the OPPTS 890.1550 Steroidogenesis (Human Cell Line H295R) protocol. Briefly, the cells were initiated from the ATCC stock and grown for 5 passages and then frozen in liquid nitrogen. Cells were then initiated from these frozen stocks and cultured for an additional 4 passages before being used for testing. The H295R media is (DMEM/H12 no phenol red Cat# 11039047 Life Technologies, Carlsbad CA; 2.5 percent Nu-Serum (Cat# 51000) + ITS Universal Culture Supplement (Cat# 40351) BD Biosciences, San Jose CA; and 0.9 percent Penicillin-Streptomycin) and the cells were maintained at 37 O C +/-1 O C, 90 percent +/-5 percent humidity, and 5 percent +/-1 percent CO 2 /air. At the time of passage, cells were dissociated from the flasks using the same procedure as for the BG1Luc4E2 cells.
For the steroidogenesis experiment, cells were plated into 24 well plates at a density of 1.3x10 5 cells/well in a volume of 1 mL per well and incubated for 24 hrs. The media was removed and replaced with fresh media supplemented with 30 µM 22-R hydroxycholesterol (Cat# H9384 Sigma Aldrich, St. Louis MO) which controls for low basal production of estradiol. Dilutions of the known inducer Forskolin (Cat# F3917, Sigma Aldrich, St. Louis MO and inhibitor Prochloraz (Cat# 45631, Sigma Aldrich, St. Louis MO) and NTO were made using DMSO; see Table 3 . The negative control for the assay is vehicle only (0.1 percent DMSO). Ten microliters of each diluted stock was added to triplicate wells. An additional triplicate set of negative control wells were prepared for the viability assay. The treated plates were returned to the incubator for 48 hours. After the 48-hour incubation cells were observed microscopically for morphological indications of cytotoxicity. Then, 30 minutes prior to collecting supernatants for hormone analysis, the supernatant was first removed from the second set of negative control wells and 400 µL of 70 percent methanol (in PBS) was added. The 30 minute incubation in 70 percent methanol kills all the cells in the well and is used as a reference point in the viability assay. After the 30 minute incubation, the supernatant from each well was collected and stored at -80 O C until analysis. After supernatant removal, the wells were washed 3 times with 400 µL PBS (Dulbecco's PBS with Ca +2 and Mg
+2
-Cat# SH30264FS, ThermoFisher, Pittsburg PA) and then stained with the Live/Dead ® assay reagents (Cat# L3224, Life Technologies, Carlsbad CA) to measure viability and cell death. The protocol provided with the assay was followed. Briefly, after the 3 PBS washes to remove residual media constituents, 300 µL of PBS was added to each well followed by 300 µL the Live/Dead working solution (10 µL Ethidium homodimer-1 (EthD-1) and 6 µL Testosterone levels were measured using a TOSOH Biosciences system (TOSOH Corp. Tokyo Japan) using ST AIA-PACK testosterone test cups (Cat # 025204; Lot 72) and following the manufacturers protocol. The assay is a competitive enzyme immunoassay (EIA) in which the test sample testosterone competes with a enzyme-labeled testosterone for a limited number of binding sites on an immobilized monoclonal antibody. After incubation with a fluorogenic substrate, the resulting intensity of fluorescence is inversely proportional to the amount of test sample testosterone. The amount of testosterone induced or inhibited by the test/control chemicals was calculated by subtracting the treated sample values from the basal (vehicle control) sample values.
Steroidogenesis Assay BLTK1 cell line
In collaboration with Dr. Tim Zacharewski, (Center for Integrative Toxicology, Michigan State University, East Lansing MI), NTO was tested for steroidogenic activity using a murine Leydig cell line. A 19 mg/mL stock solution of NTO dissolved in DMSO was provided to the collaborator. Using an approach similar to the H295R assay and described in Forgacs et al (Forgacs et al.) BLTK1 cells were exposed to 0.03, 0.1, 0.3, 1, 3, 10, 30, and 100 µM NTO. The positive control for this assay was recombinant human chorionic gonadotropin (rhCG) which induces testosterone production. Cytotoxicity of NTO was measured using an MTT assay. Testosterone was detected using a 96-well plate format EIA (Cat#582701 Cayman Chemical, Ann Arbor MI). Data were analyzed by comparing the vehicle control values to the test and positive control values. Test values that generated a 50 percent change compared to the controls were considered significant.
Results
Estrogen and Androgen Receptor Binding
The results of the estrogen and androgen receptor binding assay were negative for all NTO concentrations tested. The detailed data report is provided in Appendix B.
Aromatase Inhibition Assay
The results of the aromatase inhibition assay were negative for all NTO concentrations tested. The percent inhibition of the positive control inhibitor, ketoconazole and NTO are shown in Figure 1 . There was no statistical difference between any of the NTO test values compared to the no inhibitor values (Mann-Whitney Rank Sum, P=0.7; SigmaStat 3.11). Based on the lack of difference between the no inhibitor control and the NTO values, all of the NTO values were averaged together for Figure  1 . The data from duplicate experiments performed on separate days were averaged together. The error bars are +/-S.D.
Estrogen Receptor Transactivation Assay
The BG1Luc4E2 estrogen receptor was not activated by NTO. In contrast, the known estrogen receptor ligands (estradiol, DES, ethylparaben and methoxychlor) did activate the receptor yielding an increased production of the luciferase reporter. The results are presented in Figure 2 . The estrogenic controls responded as expected and met the criteria described in the NICEATM protocol. The relative luminescence units (RLU) considered significantly different from baseline is 26.9 x1000 RLU, see Figure 2 . The highest concentration of NTO tested, 25 µg/mL or 192 µM, was slightly above this level at 36.2 x1000 RLU.
However, the next lowest NTO concentration, 5 µg/mL or 38 µM, did not exceed this minimum positive level. Additionally, both methoxychlor and ethylparaben which are considered weak positive controls exhibit a 10-fold greater response compared to NTO. Based on these observations, NTO is not considered an estrogen receptor ligand in this assay.
Steroidogenesis Assay H295R cell line
The steroidogenesis assay using the H295R cell line evaluated both cytotoxicity and steroidogenic potential of NTO. Cytotoxicity was measured by comparing fluorescent endpoints for viable and nonviable cells. At all concentrations tested, NTO was not found to significantly affect the viability of H295R cells; see Figure 3 . The ability for NTO to inhibit or induce testosterone was assessed by measuring the level of testosterone produced from H295R cells exposed to NTO. When compared to the level of testosterone produced in cells exposed to either a known inducer (forskolin) or known inhibitor (prochloraz), NTO responses were not different from the vehicle control testosterone levels; see Figure 4 . 
Steroidogenesis Assay BLTK1 cell line
The BLTK1 cell line assay evaluated both the cytotoxicity and steroidogenic potential of NTO. Cytotoxicity was measured using the MTT assay and NTO was found to not be cytotoxic to BLTK1 cells, either in the presence or absence of rhCG; see Figure 5 . The induction and inhibition of testosterone production was measured by treating cells with NTO in the presence or absence of rhCG. In the absence of rhCG, NTO did not stimulate the production of testosterone. In the presence of rhCG, NTO did not reduce the production of testosterone; see Figure 6 . Combined, the results indicate that NTO does not impact the steroidogenesis pathway in BLTK1 cells. 
Discussion
General
The tiered approach to screening a chemical of concern permits increased focus on specific toxic responses. The testicular toxicity of NTO observed in subacute and subchronic oral toxicity rat studies warranted further exploration into the mode of action for the observed findings. One mode of testicular toxicity is through endocrine signaling, specifically via inhibition of testosterone production or function. The in vitro assays used here screened NTO for interaction with the predominant gonadal hormones: estrogen and androgen.
The results from the estrogen receptor binding, estrogen receptor activation, androgen receptor binding, aromatase inhibition, and steroidogenesis were consistently negative. No interactions between NTO and these assays were identified; see Table 4 .
Areas of Uncertainty
The in vitro assays used to screen for EDC activity gave consistent and robust results. However, the in vitro assays are not able to capture toxic effects as a result of metabolism of the parent compound. Additionally, the in vivo steroidogenic pathway is quite complex and each in vitro endpoint tested offers only a snapshot of likely interactions at the molecular level. The use of both the H295R and BLTK1 cell lines for the steroidogenesis assay improves the strength of the test as there are subtle differences between these two cell lines. Indeed, the BLTK1 cell line may be a better testes model as the cell of origin is a Leydig cell, the steroidogenic cell population in the testes (Forgacs et al.) . The in vitro assays do not evaluate endpoints within the larger Hypothalmo-Pituitary-Gonadal (HPG) axis such as follicular stimulating hormone (FSH) or luteinizing hormone (LH). 
Recommendations
The in vitro portions are complete for the EDC tier 1 evaluation of NTO. If testicular toxicity of NTO is a priority concern, the in vitro assays could be used to screen metabolites of NTO. Thus far, urazole has been identified as metabolite in isolated rat hepatocytes (Le Campion et al., 1997; Le Campion et al., 1998) . Urazole is commercially available and it is recommended that it be screened with the EDC in vitro assays.
To ascertain the affected cell populations in vivo, short duration timed NTO exposures where testes are harvested at 24 hr intervals are recommended. Histopathology of these tissues would characterize the order of cells impacted by NTO and provide a likely mode of action for testicular toxicity of NTO.
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